iBio reported first quarterly revenue of $100K amid deepened Q3 operating losses to -$8.4M from -$4.9M YoY, driven by accelerated R&D on IBIO-600/610 programs and preclinical assets, while EPS improved to -$0.06 from -$0.49 due to share dilution.
Key takeaways
Revenue was $100.0K ($0.00) as initial recognition from pipeline commercialization efforts began.
Operating Income was -$8.4M (-71.4%) reflecting increased R&D spending on consultants and services for NHP studies and CMC activities supporting IBIO-600, IBIO-610, and preclinical assets.
Net Income was -$7.7M (-59.0%) with operating losses widened by R&D acceleration in a competitive biotech environment with liquidity challenges.
EPS was $-0.06 (87.8%) improved from prior year due to larger share count following equity financing to fund operations.
Operating cash flow was -$17.0M reflecting sustained investment in R&D pipeline amid ongoing net losses and negative cash flows from operations.